Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells.

Göbel K, Pankratz S, Asaridou CM, Herrmann AM, Bittner S, Merker M, Ruck T, Glumm S, Langhauser F, Kraft P, Krug TF, Breuer J, Herold M, Gross CC, Beckmann D, Korb-Pap A, Schuhmann MK, Kuerten S, Mitroulis I, Ruppert C, Nolte MW, Panousis C, Klotz L, Kehrel B, Korn T, Langer HF, Pap T, Nieswandt B, Wiendl H, Chavakis T, Kleinschnitz C, Meuth SG.

Nat Commun. 2016 May 18;7:11626. doi: 10.1038/ncomms11626.

2.

The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style.

Margheri F, Luciani C, Taddei ML, Giannoni E, Laurenzana A, Biagioni A, Chillà A, Chiarugi P, Fibbi G, Del Rosso M.

Oncotarget. 2014 Mar 30;5(6):1538-53.

3.

Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM).

Xu X, Cai Y, Wei Y, Donate F, Juarez J, Parry G, Chen L, Meehan EJ, Ahn RW, Ugolkov A, Dubrovskyi O, O'Halloran TV, Huang M, Mazar AP.

PLoS One. 2014 Jan 21;9(1):e85349. doi: 10.1371/journal.pone.0085349. eCollection 2014. Erratum in: PLoS One. 2014;9(6):e99911.

4.

Small-molecule inhibition of the uPAR·uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis.

Mani T, Wang F, Knabe WE, Sinn AL, Khanna M, Jo I, Sandusky GE, Sledge GW Jr, Jones DR, Khanna R, Pollok KE, Meroueh SO.

Bioorg Med Chem. 2013 Apr 1;21(7):2145-55. doi: 10.1016/j.bmc.2012.12.047. Epub 2013 Jan 9.

5.

VEGF-initiated angiogenesis and the uPA/uPAR system.

Breuss JM, Uhrin P.

Cell Adh Migr. 2012 Nov-Dec;6(6):535-615. doi: 10.4161/cam.22243. Epub 2012 Oct 17. Review.

6.

Design, synthesis, biochemical studies, cellular characterization, and structure-based computational studies of small molecules targeting the urokinase receptor.

Wang F, Eric Knabe W, Li L, Jo I, Mani T, Roehm H, Oh K, Li J, Khanna M, Meroueh SO.

Bioorg Med Chem. 2012 Aug 1;20(15):4760-73. doi: 10.1016/j.bmc.2012.06.002. Epub 2012 Jun 12.

7.

Role of integrins in regulating proteases to mediate extracellular matrix remodeling.

Yue J, Zhang K, Chen J.

Cancer Microenviron. 2012 Dec;5(3):275-83. doi: 10.1007/s12307-012-0101-3. Epub 2012 Mar 22.

8.

Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis.

Wang F, Li J, Sinn AL, Knabe WE, Khanna M, Jo I, Silver JM, Oh K, Li L, Sandusky GE, Sledge GW, Nakshatri H, Jones DR, Pollok KE, Meroueh SO.

J Med Chem. 2011 Oct 27;54(20):7193-205. doi: 10.1021/jm200782y. Epub 2011 Oct 4.

10.

Hepatocyte growth factor (HGF) modulates GABAergic inhibition and seizure susceptibility.

Bae MH, Bissonette GB, Mars WM, Michalopoulos GK, Achim CL, Depireux DA, Powell EM.

Exp Neurol. 2010 Jan;221(1):129-35. doi: 10.1016/j.expneurol.2009.10.011. Epub 2009 Oct 22.

11.

Urokinase receptor mediates lung fibroblast attachment and migration toward provisional matrix proteins through interaction with multiple integrins.

Zhu S, Gladson CL, White KE, Ding Q, Stewart J Jr, Jin TH, Chapman HA Jr, Olman MA.

Am J Physiol Lung Cell Mol Physiol. 2009 Jul;297(1):L97-108. doi: 10.1152/ajplung.90283.2008. Epub 2009 May 1.

12.

Participation of the urokinase receptor in neutrophil efferocytosis.

Park YJ, Liu G, Tsuruta Y, Lorne E, Abraham E.

Blood. 2009 Jul 23;114(4):860-70. doi: 10.1182/blood-2008-12-193524. Epub 2009 Apr 27.

13.

A dual role for caveolin-1 in the regulation of fibronectin matrix assembly by uPAR.

Monaghan-Benson E, Mastick CC, McKeown-Longo PJ.

J Cell Sci. 2008 Nov 15;121(Pt 22):3693-703. doi: 10.1242/jcs.028423. Epub 2008 Oct 28.

14.

Ligand-engaged urokinase-type plasminogen activator receptor and activation of the CD11b/CD18 integrin inhibit late events of HIV expression in monocytic cells.

Alfano M, Mariani SA, Elia C, Pardi R, Blasi F, Poli G.

Blood. 2009 Feb 19;113(8):1699-709. doi: 10.1182/blood-2008-02-138412. Epub 2008 Oct 21.

15.

In silico docking of urokinase plasminogen activator and integrins.

Degryse B, Fernandez-Recio J, Citro V, Blasi F, Cubellis MV.

BMC Bioinformatics. 2008 Mar 26;9 Suppl 2:S8. doi: 10.1186/1471-2105-9-S2-S8.

16.

Structural basis of interaction between urokinase-type plasminogen activator and its receptor.

Barinka C, Parry G, Callahan J, Shaw DE, Kuo A, Bdeir K, Cines DB, Mazar A, Lubkowski J.

J Mol Biol. 2006 Oct 20;363(2):482-95. Epub 2006 Aug 26.

17.
18.

Regulation of alpha5beta1 integrin conformation and function by urokinase receptor binding.

Wei Y, Czekay RP, Robillard L, Kugler MC, Zhang F, Kim KK, Xiong JP, Humphries MJ, Chapman HA.

J Cell Biol. 2005 Jan 31;168(3):501-11.

19.

The syndecan-1 ectodomain regulates alphavbeta3 integrin activity in human mammary carcinoma cells.

Beauvais DM, Burbach BJ, Rapraeger AC.

J Cell Biol. 2004 Oct 11;167(1):171-81.

20.

Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo.

Ling Q, Jacovina AT, Deora A, Febbraio M, Simantov R, Silverstein RL, Hempstead B, Mark WH, Hajjar KA.

J Clin Invest. 2004 Jan;113(1):38-48.

Items per page

Supplemental Content

Write to the Help Desk